Similar to TNBC, in high-grade serous ovarian cancer, where more than 95% of the tumors harbor p53 mutations, ERβ2 was found to partner with mutant p53 to increase the transcription of FOXM1, leading to enhanced proliferation and therapy resistance [78]. This evidence concerns the gene TP53 and ovarian serous adenocarcinoma.